| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | TSG10; VPS23 |
| Entrez GeneID | 7251 |
| clone | 5H2A12 |
| WB Predicted band size | 44kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TSG101 (AA: 167-374) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与TSG101抗体相关的经典文献，涵盖功能研究和应用场景：
---
1. **文献名称**：*TSG101: A Novel Tumor Susceptibility Gene Isolated by Controlled Homozygous Functional Knockout*
**作者**：Li L. et al. (1997)
**摘要**：该研究首次克隆并鉴定了TSG101基因，发现其在肿瘤抑制中的关键作用。通过基因敲除实验证明TSG101缺失导致细胞周期紊乱和肿瘤形成，并开发了特异性抗体用于检测其蛋白质表达水平，为后续功能研究奠定基础。
---
2. **文献名称**：*Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding*
**作者**：Garrus J.E. et al. (2001)
**摘要**：文章揭示了TSG101在HIV病毒出芽中的核心作用，通过ESCRT-I复合体介导病毒颗粒释放。研究中利用TSG101抗体进行免疫共沉淀和免疫荧光实验，证明抑制TSG101功能可阻断病毒释放，为抗病毒治疗提供靶点。
---
3. **文献名称**：*The Role of TSG101 in Cancer: From Sporadic Tumors to Chromosomal Instability*
**作者**：Wagner K.W. et al. (2003)
**摘要**：该研究分析了TSG101在多种癌症中的表达异常，发现其在乳腺癌和卵巢癌中频繁发生突变或缺失。通过Western blot和免疫组化(使用TSG101抗体)验证其表达下调与肿瘤恶性程度相关，提示其作为预后标志物的潜力。
---
4. **文献名称**：*ESCRT-III Recognition by VPS4 ATPases*
**作者**：Morita E. & Sundquist W.I. (2019)
**摘要**：综述性研究总结了TSG101在ESCRT机制中的分子功能，强调其与VPS4蛋白的互作调控膜重塑过程。文中提到TSG101抗体用于解析蛋白质复合体结构及动态变化，为膜生物学研究提供工具支持。
---
这些文献覆盖了TSG101在肿瘤抑制、病毒出芽和细胞膜动力学中的功能，并展示了抗体在机制研究中的应用场景(如蛋白检测、定位和互作验证)。
The TSG101 (Tumor Susceptibility Gene 101) antibody is a key tool for studying the TSG101 protein, a component of the ESCRT (Endosomal Sorting Complex Required for Transport) machinery. TSG101 plays critical roles in cellular processes such as endosomal sorting, viral budding, and cytokinesis. It contains a ubiquitin-enzyme variant (UEV) domain that binds ubiquitinated cargo, facilitating the sorting of proteins into multivesicular bodies (MVBs) for lysosomal degradation or extracellular vesicle secretion. TSG101 is also essential for the release of enveloped viruses, including HIV-1. by mediating membrane scission during viral budding.
First identified in 1997 for its role in HIV-1 particle formation, TSG101 later gained attention in cancer research due to its dual role as a tumor suppressor and potential oncogene, depending on cellular context. Dysregulation of TSG101 is linked to cancers such as breast, ovarian, and liver malignancies. TSG101 antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate its expression, localization, and interactions with partners like HRS (ESCRT-0) or ALIX (ESCRT-associated). These antibodies are often validated in knockdown or knockout models to ensure specificity. Researchers rely on TSG101 antibodies to explore ESCRT-mediated membrane remodeling, viral pathogenesis, and cancer mechanisms, making them indispensable in cell biology and biomedical studies.
×
